A phase II study evaluating a maintenance strategy of Gleevce (imatinib mesylate) and bevacizumab in patients with advanced, non-squamous, non-small cell lung cancer, following completion of first-line chemotherapy with bevacizumab

Trial Profile

A phase II study evaluating a maintenance strategy of Gleevce (imatinib mesylate) and bevacizumab in patients with advanced, non-squamous, non-small cell lung cancer, following completion of first-line chemotherapy with bevacizumab

Completed
Phase of Trial: Phase II

Latest Information Update: 03 May 2013

At a glance

  • Drugs Bevacizumab (Primary) ; Imatinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 May 2013 Additional lead tral centre added as reported by ClinicalTrials.gov.
    • 16 Sep 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 22 Oct 2008 Planned end date changed from 1 Nov 2009 to 1 Aug 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top